A UK-based KOL outlines the neuroendocrine tumor landscape, including referral pathways, primary site segmentation and treatment sequencing by grade and SSTR status. The discussion covers standard use of somatostatin analogs, PRRT, chemotherapy and targeted agents, alongside perspectives on emerging radioligands and alpha emitters.

This interview was conducted on November 14, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.